Junwei Yin, Yongli Zhao, Junping Yin, Shanshan Yang
{"title":"Efficacy of transarterial chemoembolization combined with radiofrequency ablation in the treatment of liver metastases from colorectal cancer.","authors":"Junwei Yin, Yongli Zhao, Junping Yin, Shanshan Yang","doi":"10.1007/s12094-025-03879-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Liver metastases from colorectal cancer are a common and serious complication that significantly impacts patient survival. The aim of this study is to investigate the clinical efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of liver metastases from colorectal cancer.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 120 patients with liver metastases from colorectal cancer who were treated in our hospital from January 2018 to January 2023. The patients were divided into two groups based on the treatment they received: the TACE group (n = 60) and the TACE combined with RFA group (n = 60). The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were compared between the two groups, and treatment-related adverse effects were recorded.</p><p><strong>Results: </strong>The TACE combined with RFA group showed significantly better OS (22 months vs. 18 months) and PFS (13 months vs. 10 months) compared to the TACE alone group (P < 0.05). The ORR in the TACE combined with RFA group was 61.7%, significantly higher than 40% in the TACE alone group (P < 0.05). The DCR showed no significant difference between the two groups, with 86.7% (52/60) in the TACE combined with RFA group and 78.3% (47/60) in the TACE alone group (P > 0.05). There were no significant differences in treatment-related adverse effects between the two groups (P > 0.05).</p><p><strong>Conclusion: </strong>These findings suggest that TACE combined with RFA may offer a potential option for improving OS, PFS, and ORR in patients with liver metastases from colorectal cancer, without increasing significant adverse effects, setting a new potential standard of care in the treatment of this disease.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03879-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Liver metastases from colorectal cancer are a common and serious complication that significantly impacts patient survival. The aim of this study is to investigate the clinical efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of liver metastases from colorectal cancer.
Methods: A retrospective analysis was conducted on 120 patients with liver metastases from colorectal cancer who were treated in our hospital from January 2018 to January 2023. The patients were divided into two groups based on the treatment they received: the TACE group (n = 60) and the TACE combined with RFA group (n = 60). The overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) were compared between the two groups, and treatment-related adverse effects were recorded.
Results: The TACE combined with RFA group showed significantly better OS (22 months vs. 18 months) and PFS (13 months vs. 10 months) compared to the TACE alone group (P < 0.05). The ORR in the TACE combined with RFA group was 61.7%, significantly higher than 40% in the TACE alone group (P < 0.05). The DCR showed no significant difference between the two groups, with 86.7% (52/60) in the TACE combined with RFA group and 78.3% (47/60) in the TACE alone group (P > 0.05). There were no significant differences in treatment-related adverse effects between the two groups (P > 0.05).
Conclusion: These findings suggest that TACE combined with RFA may offer a potential option for improving OS, PFS, and ORR in patients with liver metastases from colorectal cancer, without increasing significant adverse effects, setting a new potential standard of care in the treatment of this disease.
期刊介绍：
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
